The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A highly reproducible rotenone model of Parkinson's disease
Open accessAbstract
The systemic rotenone model of Parkinson's disease (PD) accurately replicates many aspects of the pathology of human PD and has provided insights into the pathogenesis of PD. The major limitation of the rotenone model has been its variability, both in terms of the percentage of animals that develop a clear-cut nigrostriatal lesion and the extent of that lesion. The goal here was to develop an improved and highly reproducible rotenone model of PD. In these studies, male Lewis rats in three age groups (3, 7 or 12-14 months) were administered rotenone (2.75 or 3.0 mg/kg/day) in a specialized vehicle by daily intraperitoneal injection. All rotenone-treated animals developed bradykinesia, postural instability, and/or rigidity, which were reversed by apomorphine, consistent with a lesion of the nigrostriatal dopamine system. Animals were sacrificed when the PD phenotype became debilitating. Rotenone treatment caused a 45% loss of tyrosine hydroxylase-positive substantia nigra neurons and a commensurate loss of striatal dopamine. Additionally, in rotenone-treated animals, α-synuclein and poly-ubiquitin positive aggregates were observed in dopamine neurons of the substantia nigra. In summary, this version of the rotenone model is highly reproducible and may provide an excellent tool to test new neuroprotective strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
Self-citationAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Neuropathology of Parkinsonʼs Disease
Forno, L. S. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,465
Ungerstedt, U. (1971) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.1971.tb11001.x · Cited by 1,290
Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway
Deumens, R., Blokland, A., & Prickaerts, J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7891 · Cited by 758
Sherer, T. B., Kim, J.-H., Betarbet, R., & Greenamyre, J. T. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8072 · Cited by 708
Self-citationThe risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living
Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., & Richardson, R. J. (1998) · Neurology · doi:10.1212/wnl.50.5.1346 · Cited by 639
Environmental risk factors and Parkinson's disease: A case‐control study in Taiwan
Liou, H. H., Tsai, M. C., Chen, C. J., Jeng, J. S., Chang, Y. C., Chen, S. Y., & Chen, R. C. (1997) · Neurology · doi:10.1212/wnl.48.6.1583 · Cited by 616
Gibb, W. R., & Lees, A. J. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.5.388 · Cited by 574
Occupational exposures to metals as risk factors for Parkinson's disease
Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., Kortsha, G. X., Brown, G. G., & Richardson, R. J. (1997) · Neurology · doi:10.1212/wnl.48.3.650 · Cited by 476
Cited by
Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease
Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.004 · Cited by 762
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Chin-Chan, M., Navarro-Yepes, J., & Quintanilla-Vega, B. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00124 · Cited by 707
α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease
Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., Hu, X., McCoy, J., Chu, C. T., Burton, E. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3634 · Cited by 619
Self-citationLiu, L., MacKenzie, K. R., Putluri, N., Maletić-Savatić, M., & Bellen, H. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.024 · Cited by 556
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
α-Synuclein: Membrane Interactions and Toxicity in Parkinson's Disease
Auluck, P. K., Caraveo, G., & Lindquist, S. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.042308.113313 · Cited by 519
Neurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 506
Classic and New Animal Models of Parkinson's Disease
Blesa, J., Phani, S., Jackson-Lewis, V., & Przedborski, S. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/845618 · Cited by 505
Environmental Toxins and Parkinson's Disease
Goldman, S. M. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135937 · Cited by 505
A Guide to Neurotoxic Animal Models of Parkinson's Disease
Tieu, K. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009316 · Cited by 483
Parkinson’s disease: animal models and dopaminergic cell vulnerability
Blesa, J., & Przedborski, S. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00155 · Cited by 480
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism
Hauser, D. N., & Hastings, T. G. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.011 · Cited by 474
Wagner, J., Ryazanov, S., Leonov, A., Levin, J., Shi, S., Schmidt, F., Prix, C., Pan-Montojo, F., Bertsch, U., Mitteregger-Kretzschmar, G., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1114-9 · Cited by 457
Figueira, T. R., Barros, M. H., Camargo, A. A., Castilho, R. F., Ferreira, J. C. B., Kowaltowski, A. J., Sluse, F. E., Souza-Pinto, N. C., & Vercesi, A. E. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4729 · Cited by 419
Effects and Mechanisms of Taurine as a Therapeutic Agent
Schaffer, S., & Kim, H. W. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.251 · Cited by 414
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Flint Beal, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 413
Oxidative damage to macromolecules in human Parkinson disease and the rotenone model
Sanders, L. H., & Timothy Greenamyre, J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.003 · Cited by 345
Johnson, M. E., & Bobrovskaya, L. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2014.12.002 · Cited by 332
Cicchetti, F., Drouin-Ouellet, J., & Gross, R. E. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.06.005 · Cited by 311
Population-scale single-cell RNA-seq profiling across dopaminergic neuron differentiation
Jerber, J., Seaton, D. D., Cuomo, A. S. E., Kumasaka, N., Haldane, J., Steer, J., Patel, M., Pearce, D., Andersson, M., Bonder, M. J., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00801-6 · Cited by 300
Sarkar, S., Malovic, E., Harishchandra, D. S., Ghaisas, S., Panicker, N., Charli, A., Palanisamy, B. N., Rokad, D., Jin, H., Anantharam, V., et al. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0032-2 · Cited by 285
Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment
Zeng, X.-S., Geng, W.-S., & Jia, J.-J. (2018) · ASN Neuro · doi:10.1177/1759091418777438 · Cited by 275
Rapamycin protects against rotenone-induced apoptosis through autophagy induction
Pan, T., Rawal, P., Wu, Y., Xie, W., Jankovic, J., & Le, W. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.08.014 · Cited by 273
Toxin Models of Mitochondrial Dysfunction in Parkinson's Disease
Martinez, T. N., & Greenamyre, J. T. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4033 · Cited by 266
Self-citationChronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology
Drolet, R. E., Cannon, J. R., Montero, L., & Greenamyre, J. T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.017 · Cited by 257
Self-citationAre synucleinopathies prion-like disorders?
Angot, E., Steiner, J. A., Hansen, C., Li, J.-Y., & Brundin, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70213-1 · Cited by 251
St. Laurent, R., O’Brien, L. M., & Ahmad, S. T. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.037 · Cited by 199
The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease
Hastings, T. G. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9257-z · Cited by 199
“Despite the ubiquitous nature of the rotenone-induced Complex I inhibition, DA neurons were the most vulnerable to degeneration which mimics the loss of DA neurons in PD (Betarbet et al. 2000; Betarbet et al. 2006; Cannon et al. 2009).”
BackgroundNeurotoxins: Free radical mechanisms and melatonin protection
J. Reiter, R., C. Manchester, L., & Tan, D.-X. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246236 · Cited by 179
Katila, N., Bhurtel, S., Shadfar, S., Srivastav, S., Neupane, S., Ojha, U., Jeong, G.-S., & Choi, D.-Y. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.015 · Cited by 169
Bhattarai, Y., Si, J., Pu, M., Ross, O. A., McLean, P. J., Till, L., Moor, W., Grover, M., Kandimalla, K. K., Margolis, K. G., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2020.1866974 · Cited by 126
Tapias, V., Hu, X., Luk, K. C., Sanders, L. H., Lee, V. M., & Greenamyre, J. T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2541-x · Cited by 126
Self-citationMembers, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124
“Furthermore, ASYN protofibrils interact with intracellular organelles such as neurotransmitter vesicles or mitochondria, and lead to an uncontrolled release of DA and an impairment of mitochondrial function (Lotharius et al.”
BackgroundInfluentialJohnson, M. E., Stringer, A., & Bobrovskaya, L. (2018) · NeuroToxicology · doi:10.1016/j.neuro.2018.02.013 · Cited by 122
Comparative neurotoxicity screening in human iPSC-derived neural stem cells, neurons and astrocytes
Pei, Y., Peng, J., Behl, M., Sipes, N. S., Shockley, K. R., Rao, M. S., Tice, R. R., & Zeng, X. (2016) · Brain Research · doi:10.1016/j.brainres.2015.07.048 · Cited by 128
Foguth, R. M., Flynn, R. W., de Perre, C., Iacchetta, M., Lee, L. S., Sepúlveda, M. S., & Cannon, J. R. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114623 · Cited by 103
Self-citationSikorska, M., Lanthier, P., Miller, H., Beyers, M., Sodja, C., Zurakowski, B., Gangaraju, S., Pandey, S., & Sandhu, J. K. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.032 · Cited by 70
Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease
González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65
Wu, Z., Xia, Y., Wang, Z., Su Kang, S., Lei, K., Liu, X., Jin, L., Wang, X., Cheng, L., & Ye, K. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0687-7 · Cited by 41
Kulcsarova, K., Bang, C., Berg, D., & Schaeffer, E. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-230206 · Cited by 40
Yurtsever, İ., Üstündağ, Ü. V., Ünal, İ., Ateş, P. S., & Emekli-Alturfan, E. (2022) · Drug and Chemical Toxicology · doi:10.1080/01480545.2020.1846549 · Cited by 39
“Amounts of rotenone and rifampicin administered were determined according to nontoxic values in similar studies (Oida et al. 2006; Cannon et al. 2009).”
Wise, J. P., & Cannon, J. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw133 · Cited by 20
Self-citation
Metadata
- Authors
- Cannon, J. R., Tapias, V., Na, H. M., Honick, A. S., Drolet, R. E., & Greenamyre, J. T.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 34
- Issue
- 2
- Pages
- 279-290
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2029503022
- Cited by
- 795
- References
- 36
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.